- Home
- LYFT vs GPCR Comparison
LYFT vs GPCR Comparison
Compare LYFT & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LYFT | GPCR |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.3B |
| IPO Year | 2019 | 2023 |
Fundamental Metrics
Financial Performance| Metric | LYFT | GPCR |
|---|---|---|
| Price | $16.64 | $78.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 31 | 12 |
| Target Price | $22.50 | ★ $103.09 |
| AVG Volume (30 Days) | ★ 13.7M | 1.3M |
| Earning Date | 02-10-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $6,273,827,000.00 | N/A |
| Revenue This Year | $14.26 | N/A |
| Revenue Next Year | $13.67 | N/A |
| P/E Ratio | $45.37 | ★ N/A |
| Revenue Growth | ★ 14.90 | N/A |
| 52 Week Low | $9.66 | $13.22 |
| 52 Week High | $25.54 | $94.90 |
Technical Indicators
Market Signals| Indicator | LYFT | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 38.95 | 50.79 |
| Support Level | $15.68 | $72.10 |
| Resistance Level | $18.07 | $92.06 |
| Average True Range (ATR) | 0.76 | 4.35 |
| MACD | -0.07 | -2.61 |
| Stochastic Oscillator | 30.51 | 32.39 |
Price Performance
Historical ComparisonAbout LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.